Safety & Efficacy Study of FemFlow Drug-Eluting Peripheral Balloon

Status Recruiting

Clinical Trial Summary

A prospective, multi-centre, objective performance criteria clinical trial to evaluate the safety and efficacy of FemFlow Drug-Eluting Peripheral Balloon Catheter manufactured by Lifetech Scientific (Shenzhen) Co., LTD. for lesions with femoropopliteal artery stenosis or occlusion.

Clinical Trial Description

This study is a prospective, multi-centre, single-group target value clinical study. Taking the patency rate at 12 months after operation as the primary evaluation index and taking target vascular cavity loss rate at 6 months postoperatively, Rutherford Classification at 12 months postoperatively, the ankle/brachial index (ABI), revascularization rate of target lesions, revascularization rate of target vessels, operating success rate and success rate of surgery as the secondary evaluation indexes to evaluate the efficacy of FemFlow Drug-Eluting Peripheral Balloon Catheter manufactured by Lifetech Scientific (Shenzhen) Co., LTD. for lesions with femoropopliteal artery stenosis or occlusion. Taking the incidence of major adverse events (MAE), adverse events (AE) and instrument defects occurred through the entire trail as the evaluation indexes to evaluate the safety of FemFlow Drug-Eluting Peripheral Balloon Catheter manufactured by Lifetech Scientific (Shenzhen) Company for lesions with femoropopliteal artery stenosis or occlusion. According to statistical hypothesis and sample size calculation, the sample size of this clinical trial was 208 cases. All subjects were followed up 1 month, 6 months and 12 months after treatment with a FemFlow Drug-Eluting Peripheral Balloon Catheter, and data on efficacy and safety were collected. All relevant clinical data are managed and analyzed by the professional data management centre and the statistical centre. End-point events of clinical trials are determined by a specially established third party. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03683459
Study type	Interventional
Source	Lifetech Scientific (Shenzhen) Co., Ltd.
Contact	Ying Xia
Phone	+86 13760184511
Email	xiaying@lifetechmed.com
Status	Recruiting
Phase	N/A
Start date	July 18, 2018
Completion date	December 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01947478` - MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery	N/A
Recruiting	`NCT03687983` - Safety and Efficacy Study of GoldenFlow Peripheral Stent System	N/A
Completed	`NCT02720003` - A Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal Arteries	N/A
Completed	`NCT02063672` - Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis	N/A
Completed	`NCT01816412` - LEVANT Japan Clinical Trial	Phase 2
Completed	`NCT01566461` - IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery (SFA) and Proximal Popliteal Artery (PPA)	N/A
Completed	`NCT01412541` - Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal Arteries	N/A
Recruiting	`NCT03142347` - Remote Endarterectomy vs Remote Endarterectomy + Drug Coated Balloon (DCB) Angioplasty in Patients With the Femoral Artery Occlusive Disease	N/A
Terminated	`NCT00810134` - Bypass or Thurpass for Superficial Femoral Artery Occlusion? Scandinavian Thurpass Study	N/A
Active, not recruiting	`NCT05734157` - CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery	N/A
Completed	`NCT02013271` - Lutonix® DCB for Treatment of Long Lesions in Femoropopliteal Arteries
Completed	`NCT04343196` - Digital Variance Angiography in Diagnostic Angiographies for Effective Radiation Dose Reduction	N/A
Terminated	`NCT02813577` - Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries in United States Females (CONFIRM)	N/A
Completed	`NCT03844724` - Drug-eluting PTA Balloon Dilatation Catheter in the Treatment of Peripheral Artery Stenosis or Occlusion	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Safety and Efficacy Study of FemFlow Drug-Eluting Peripheral Balloon Catheter

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms